Find Academic Supervisors

• Breast Cancer
• Ovarian Cancer
• BRCA1
• +4 more

Annette Gerritsen is an active Researcher in the Department of Medical Oncology at Erasmus MC, Erasmus University Rotterdam, specializing in hereditary cancer syndromes with focus on Breast Cancer , Ovarian Cancer , and BRCA1/2 mutation carriers . Her work bridges oncology and cardiovascular outcomes in high-risk populations. Her research interests center on cancer risk assessment in genetic syndromes, particularly examining contralateral cancer development , salpingo-oophorectomy outcomes , and multi-site cancer risks in CHEK2 families. Current work investigates cardiovascular implications of risk-reducing surgeries using advanced imaging techniques. Recent publications (2024-2025) reveal a strong focus on cardio-oncology interfaces , with multiple studies analyzing arterial stiffness and coronary calcium scores post-salpingo-oophorectomy in BRCA carriers. Her work consistently employs multicenter prospective designs and radiological biomarker analysis . Scientific contributions: Active contributor to The Hereditary Breast and Ovarian Cancer Research Group Netherlands ORCID: 0000-0002-9724-6693 44 total research outputs including 41 articles She has supervised at least one doctoral project and collaborates extensively with national consortia including Ausems, van Leeuwen, and Maas groups. Current work emphasizes longitudinal monitoring of surgical risk-reduction outcomes and genetic risk stratification models.

Rhian GabeView profile

Professor

• Biostatistics
• Clinical Trials
• Cancer Screening
• +4 more

Professor Rhian Gabe is a Professor of Biostatistics and Clinical Trials at Queen Mary University of London, affiliated with the Wolfson Institute of Population Health and the Faculty of Medicine and Dentistry. She leads the Centre for Evaluation and Methods and directs the Barts Clinical Trials Unit. Her expertise spans medical statistics, clinical trials, and epidemiology, with a focus on cancer screening, prevention, and addressing health inequalities. Education: BSc in Mathematics (University of Liverpool), MSc in Epidemiology (University of Cambridge), PhD in Biostatistics (Queen Mary University of London). Research interests include cancer detection and treatment, infectious diseases, and public health interventions. She has led trials in prostate cancer imaging, lung cancer screening, and smoking cessation for tuberculosis patients. Her work emphasizes methodological rigor and reducing health disparities. Notable roles include leading the Yorkshire Lung Screening Trial and contributing to international studies on HIV prevention and venous leg ulcers. Her supervision spans projects on lung nodule risk assessment, breast screening strategies, and colorectal cancer modeling. She collaborates with institutions worldwide and holds grants from Barts Charity, NIHR, and the Wolfson Institute.

Pankaj Kumar ChoudharyView profile

Professor

• Biostatistics
• Statistical Methodology
• Method Comparison Studies
• +4 more

Pankaj Kumar Choudhary is a Professor in the Department of Mathematical Sciences at the University of Texas at Dallas. His academic credentials include a B.Sc. in Statistics from the University of Delhi (1996), M.Sc. in Statistics from Indian Institute of Technology Kanpur (1998), and Ph.D. in Statistics from Ohio State University (2002). Contact information includes office FO 2.408B, phone 972-883-4436, and email pankaj@utdallas.edu. Dr. Choudhary's research focuses on biostatistics, statistical methodology, method comparison studies, and risk prediction. He has developed specialized statistical models including the CBCRisk calculator for contralateral breast cancer prediction and has published extensively on functional data analysis, Bayesian modeling, and measurement error methodologies. His recent publications (2016-2023) demonstrate strong emphasis on medical applications of statistics, particularly in oncology and substance abuse research. Trends include Bayesian learning models for cannabis use disorder, personalized cancer risk prediction frameworks, functional data tolerance bands, and methodological advances in statistical comparison studies. He has co-authored two significant books: Ordered Data Analysis, Modeling and Health Research Methods (Springer, 2015) and Measuring Agreement: Models, Methods, and Applications (Wiley, 2017) with companion R resources. He has taught specialized short courses on method comparison data analysis and statistical machine learning at international venues.

• Health Services Research
• Geriatric Oncology
• Psycho-Oncology
• +4 more

Karen A Collins is a Professor of Health Services Research at Sheffield Hallam University's Centre for Health and Social Care Research. Her academic work focuses on geriatric oncology, psycho-oncology, and patient-centered decision-making in cancer care. Research areas: Health services for elderly cancer patients, radiation therapy outcomes, quality of life metrics Key contributions: Cluster RCT on early breast cancer treatment protocols, observational studies on radiation therapy utilization Collaborators: Lynda Wyld, Malcolm Reed, Stephen Walters, Maria Burton Recent publications analyze contralateral mastectomy impacts, caregiver decision-making roles in dementia-cancer cases, and psychosocial trade-offs in cancer treatment. She contributes to developing evidence-based guidelines for elderly cancer patients.

Roderick ClarkView profile

Assistant Professor

• Epidemiology
• Genetics
• Personalized medicine
• +4 more

Roderick Clark, MD, MSc is an Assistant Professor in the Department of Urology and the Department of Public Health Sciences at Penn State College of Medicine. He is affiliated with the Penn State Cancer Institute where he specializes in Cancer Control research and provides clinical care at the Penn State Cancer Institute and Penn State Health Surgery Specialties in Hershey, PA. Dr. Clark earned his Doctor of Medicine from Dalhousie University Faculty of Medicine (Canada) in 2015, completed his Urology Residency at the University of Western Ontario (2015-2020), and pursued fellowship training in Urologic Oncology Surgery at the University of Toronto (2020-2022). He also holds a Master of Science in Community Health and Epidemiology from Dalhousie University. Dr. Clark's research focuses on the epidemiology, genetics, and clinical management of urologic cancers, with particular emphasis on prostate cancer. His work aims to better identify and treat high-risk individuals and examines changing population-level trends using large administrative databases. Clinically, he has advanced expertise in MRI and micro-ultrasound targeted prostate biopsy, transperineal prostate biopsy, focal therapies for prostate cancer (including high-intensity focused ultrasound), SpaceOAR hydrogel administration, robotic prostate cancer surgery, and salvage procedures. His recent publications demonstrate a focused research trajectory in prostate cancer management, testicular cancer outcomes, and innovative urologic oncology approaches. His scholarly work spans epidemiological studies, clinical management strategies, and surgical innovations with particular attention to high-risk prostate cancer, testicular teratoma, and optimized treatment protocols. Dr. Clark has received multiple teaching awards recognizing his excellence in medical education: University of Toronto MD Teaching Excellence Award University of Western Ontario Resident Teaching Award (awarded three times) UWO Class of Meds' 49 Award for Excellence in Teaching by a Resident UWO Department of Surgery Dr. Murray Girotti Award for Best Resident Teacher Annual Symposium Best Student Poster award Dalhousie Medical Research Development Office Payzant award Division of Urology Resident Teaching Award As a dedicated educator, Dr. Clark serves as a problem-based learning facilitator at the Penn State Health Milton S. Hershey Medical Center and actively participates in the Department of Urology educational mandate. His clinical practice encompasses management of benign prostatic hypertrophy, urologic oncology, and endourology procedures. Dr. Clark contributes to UN Sustainable Development Goals related to health and well-being through his research and clinical work in advancing cancer care and improving patient outcomes.

• Breast Cancer
• Proton Therapy
• Radiation Therapy
• +3 more

Dr. Margriet Sattler is a Researcher at Erasmus MC in the Radiotherapy department. Her work focuses on optimizing radiation therapy techniques to minimize long-term complications while improving cancer treatment outcomes. PhD in Medical Sciences External position at Holland Proton Therapy Center (Holland PTC) since March 2016 Research Interests: Dr. Sattler specializes in breast cancer radiotherapy , proton therapy applications , and radiation-induced cardiovascular risks . Her work explores: Advanced radiation delivery methods (VMAT, IMPT) Dose optimization algorithms Long-term survivorship effects Genetic factors in radiation toxicity (BRCA1/2) Collaborative Trends: Recent projects involve international teams analyzing radiation dose impacts, developing AI-driven treatment planning tools, and studying secondary cancer risks post-radiotherapy.

Kevin C WelchView profile

Professor

• Rhinology
• Skull Base Surgery
• Head and Neck Cancer
• +3 more

Kevin C Welch, MD, is a Professor in the Department of Otolaryngology - Head and Neck Surgery at Northwestern University's Feinberg School of Medicine, practicing at Northwestern Memorial Hospital. His clinical expertise centers on complex rhinological and skull base disorders, including endoscopic management of sinus tumors and cerebrospinal fluid leaks. Education: BA: University of Pennsylvania (1995) MD: MCP-Hahnemann University School of Medicine (2002) Internship: Surgery, University of Maryland Medical Center (2003) Residency: Otorhinolaryngology, University of Maryland Medical Center (2007) Fellowship: Rhinology & Skull Base Surgery, University of Pennsylvania (2008) Dr. Welch's research pioneers rhinology and skull base surgery innovation, focusing on chronic sinusitis pathophysiology, surgical technique optimization, and outcomes measurement. His work bridges clinical practice with translational science, particularly in biologic therapies for inflammatory sinus disease and standardized approaches to complex skull base procedures. As an active surgical educator , he shapes next-generation specialists through formal teaching and professional society leadership. His 2025 publications reveal three critical research thrusts: 1) Molecular mechanisms in treatment-resistant rhinosinusitis, 2) Standardization of endoscopic skull base surgical techniques, and 3) Longitudinal assessment of surgical outcomes beyond immediate postoperative periods. These studies collectively advance precision medicine in sinus disorders while establishing evidence-based surgical frameworks. Scientific Awards: Educator and Researcher, Loyola University (2015) Presidential Citation, American Rhinologic Society (2014) Presidential Citation, American Rhinologic Society (2012) Dr. Welch drives academic discourse as Associate Editor of the International Forum of Allergy & Rhinology and through leadership roles including Executive Committee membership in the American Rhinologic Society. His mentorship extends through formal teaching positions and committee work focused on surgical education standards. While specific grant details aren't disclosed, his 132 publications demonstrate sustained research productivity. His clinical team operates within Northwestern Memorial Hospital's advanced otolaryngology division, utilizing cutting-edge endoscopic and image-guided technologies for complex sinus and skull base interventions.

Leila DorlingView profile

Researcher

• Breast Cancer Genetic Epidemiology
• Radiogenomics
• Genetic Susceptibility to Cancer
• +3 more

Leila Dorling is a researcher in the Department of Public Health and Primary Care at the University of Cambridge, specializing in breast cancer genetic epidemiology. She works within the Centre for Cancer Genetic Epidemiology and has been a key contributor to the Breast Cancer Association Consortium and the Radiogenomics Consortium. Her research focuses on refining breast cancer risk estimates through pedigree analysis and investigating genetic variants associated with treatment toxicity. Research Highlights: Quantifying risks of protein truncating and missense variants in breast cancer genes Developing and validating risk prediction models like CanRisk Analyzing radiation and chemotherapy-induced toxicity through GWAS Investigating hereditary cancer syndromes and global genetic associations Teaching & Collaboration: Supervises students and teaches on the MPhil in Population Health Sciences. Active in international collaborations including BRIDGES project and 113,000+ woman breast cancer risk study.

• Breast Cancer Research
• Molecular Pathology
• Cancer Genomics
• +7 more

Peter Simpson is an Associate Professor at the UQ Centre for Clinical Research and an Affiliate Associate Professor in the School of Biomedical Sciences at The University of Queensland. He serves as Theme Leader for Cancer and Group Leader in Cancer Genomics, and holds a joint teaching and research position as a Senior Lecturer in Pathology for the Faculty of Medicine MD Program. Simpson is also affiliated with the Centre for Extracellular Vesicle Nanomedicine and is a Fellow of the Faculty of Science in the Royal College of Pathologists of Australasia. Dr. Simpson's research program focuses on understanding the molecular mechanisms of cancer development and progression to improve diagnosis and patient management. His primary research interests include invasive lobular carcinoma of the breast, familial breast cancer, and lung cancer diagnostics. He has established himself as a leader in applying genomic technologies to understand cancer heterogeneity and develop better molecular classification systems that can predict tumor behavior and treatment response. Simpson's work bridges basic science with clinical applications, particularly in optimizing next-generation sequencing approaches from small diagnostic samples. His recent publications demonstrate a strong focus on breast cancer genomics, with particular emphasis on molecular subtypes, biomarkers for prognosis and treatment response, and the application of novel technologies like nanoparticle drug delivery systems for difficult-to-treat metastases. Simpson's research team also investigates lung cancer diagnostics, particularly optimizing sequencing approaches from small samples obtained through endobronchial ultrasound-guided transbronchial needle aspiration. His work spans multiple disciplines including molecular pathology, cancer genomics, and translational medicine. Dr. Simpson is a member of the International Cancer Genome Consortium (Breast Cancer group) and has been instrumental in establishing the Brisbane Breast Bank. He collaborates extensively with researchers across Australia and internationally, contributing to large consortia studies that advance our understanding of cancer genetics and genomics. His work has significant implications for precision oncology and personalized cancer treatment approaches.

Maartje J. HooningView profile

Researcher

• Cancer Epidemiology
• Hereditary Breast and Ovarian Cancer
• Risk Prediction Models
• +3 more

Maartje J. Hooning is a senior scientist and group leader in the Department of Medical Oncology at Erasmus University Medical Center , Rotterdam. She leads the Cancer Epidemiology research group, focusing on hereditary breast/ovarian cancer and late effects of cancer treatment. MD from University of Amsterdam (1990) MSc in Clinical Epidemiology PhD in Cancer Epidemiology (Netherlands Cancer Institute) Her research integrates genetic , hormonal/lifestyle , and treatment data to build risk/prognostic models for high-risk families. Current projects include: CHEK2 : Risk prediction for CHEK2 c.1100delC families HARMONY : Long-term effects of premenopausal risk-reducing salpingo-oophorectomy B2B : Online decision aid for contralateral breast cancer risk PREVOM : Impact of bilateral mastectomy on survival and anxiety in BRCA1/2 carriers Her work is supported by national collaborations (HEBON, Netherlands Cancer Institute, Radboud UMC) and international consortia (BCAC, CIMBA). Key articles highlight trends in: 2022 : Chemotherapy effects on contralateral breast cancer risk 2021 : Hormonal therapy in triple-negative breast cancer 2020 : Polygenic risk scoring for contralateral cancer 2019 : Survival outcomes after bilateral mastectomy She has supervised multiple PhD students and secured grants from KWF , Pink Ribbon , Alpe d’HuZes , and NWO for projects like the HARMONY study and CHEK2 research . Her team collaborates with Clinical Genetics , Pathology , Radiology , and Gynecological Oncology at Erasmus MC, alongside national and international partners.

• Genetic Epidemiology
• Molecular Epidemiology
• Breast Cancer Risk Assessment
• +3 more

Jonine Bernstein is a Professor at Weill Cornell Medicine's Graduate School of Medical Sciences in the Department of Population Health Sciences. She leads the WECARE Study (Women’s Environmental Cancer and Radiation Epidemiology) and co-leads the MSK Population Sciences Research Program. Education: PhD (Yale University), MS (University of Southern California), AB (Brown University) Research Interests: Genetic and molecular epidemiology of breast cancer and gliomas, with focus on DNA repair pathways, radiation-induced carcinogenesis, and biomarker development. She investigates gene-environment interactions in cancer risk and progression. Article Trends: Recent work spans multi-omics analysis in gliomas machine learning applied to radiation dosimetry telemedicine in oncology polygenic risk scores for cancer screening Scientific Leadership: She serves on the U.S. EPA Radiation Advisory Committee and the Radiation Effects Research Foundation’s Scientific Advisory Board. Awards: Henry and Alexia Fernandez Computational Oncology Fellowship

Roderick ClarkView profile

Assistant Professor

• Urologic Cancers
• Prostate Cancer
• Cancer Epidemiology
• +3 more

Roderick Clark, MD, MSc is an Assistant Professor with dual appointments in the Department of Urology and Department of Public Health Sciences at Penn State University, where he is also affiliated with the Penn State Cancer Institute's Cancer Control program. As a fellowship-trained Surgical Oncologist specializing in urologic cancers, Dr. Clark maintains an active clinical practice with comprehensive expertise in prostate cancer management across the entire care continuum from screening to end-of-life care. Penn State Cancer Institute, Cancer Control Department of Urology Department of Public Health Sciences Dr. Clark's educational background includes a Doctor of Medicine and Master of Science in Community Health and Epidemiology from Dalhousie University, followed by residency at Western University of Western Ontario, and dual fellowships in Urologic Oncology at the University of Toronto and in Familial Breast Cancer Research at Women's College Research Institute. His research program focuses on the epidemiology, genetics, and clinical management of urologic cancers, with particular emphasis on prostate cancer. Dr. Clark investigates how to better identify and treat individuals at high-risk of dying from prostate cancer and analyzes changing population-level trends in urologic cancers using large administrative databases. His research output shows increasing productivity with 9 publications in 2022 alone, totaling 31 research outputs to date. Dr. Clark has received six teaching awards during his training, including the University of Toronto MD Teaching Excellence Award and multiple University of Western Ontario teaching recognitions. He serves as a problem-based learning facilitator at the Penn State Health Milton S. Hershey Medical Center and actively participates in the Department of Urology's educational mandate. University of Toronto MD Teaching Excellence Award University of Western Ontario Resident Teaching Award (awarded three times) UWO Class of Meds' 49 Award for Excellence in Teaching by a Resident UWO Department of Surgery Dr. Murray Girotti Award for Best Resident Teacher Annual Symposium Best Student Poster award Dalhousie Medical Research Development Office Payzant award Clinically, Dr. Clark has advanced training in numerous specialized techniques including MRI and micro-ultrasound targeted prostate biopsy, transperineal prostate biopsy, focal therapies for prostate cancer (with emphasis on high-intensity focused ultrasound), SpaceOAR hydrogel administration, robotic prostate cancer surgery, and salvage pelvic lymph node dissection/metastatectomy. He maintains board eligibility with the American Board of Urology and is a Fellow of the Royal College of Surgeons of Canada.

Richard Blake RossView profile

Assistant Professor

• Radiation Oncology
• Tumor Immunology
• Head and Neck Cancers
• +7 more

Richard Blake Ross, MD is Assistant Professor of Radiation Oncology at the University of Colorado Anschutz Medical Campus and treats patients at UCHealth Memorial Hospital Central & North in Colorado Springs. He completed medical school at Case Western Reserve University (2019), internship at Memorial Sloan-Kettering Cancer Center (2020), and served as Chief Resident in Radiation Oncology at the University of Colorado (2024). Education & Training: MD – Case Western Reserve University School of Medicine, 2019 BS – University of Tennessee, 2013 Internship – Memorial Sloan-Kettering Cancer Center, 2020 Residency – University of Colorado (Chief Resident), Radiation Oncology, 2024 Research Focus: Dr Ross leads translational projects exploring how dietary fatty acids and immune modulators (PPAR-α agonists, IL-7, CGRP signalling) interact with radiotherapy in head-and-neck, pancreatic, breast and brain tumors. His work employs stereotactic radiosurgery, intensity-modulated radiotherapy and novel immunotherapy combinations to improve tumor control while limiting toxicity. Across 20 peer-reviewed articles (2016-2024) he has identified dietary oleic acid as a potential counteractor of radiation-induced immunity, demonstrated that sensory-nerve-derived CGRP suppresses tumor-infiltrating lymphocytes in HNSCC, and contributed to multi-institutional radiosurgery outcomes for breast-cancer brain metastases. Professional Memberships: American Society for Radiation Oncology (ASTRO) – Member American Society of Clinical Oncology (ASCO) – Member Clinical Practice: He specializes in radiation management of brain tumors, head-and-neck, genitourinary and gastrointestinal malignancies, emphasizing patient education and shared decision-making. He practices at UCHealth sites in Colorado Springs and holds hospital privileges at Memorial Hospital Central & North.

• Thyroid Diseases
• Endocrinology
• Thyroid Cancer
• +4 more

Trevor Angell, MD is an Associate Professor of Clinical Medicine at the Keck School of Medicine of USC . He serves as the Associate Medical Director of the Thyroid Center and is board-certified in Internal Medicine and Diabetes, Endocrinology, and Metabolism. Clinical Expertise: Thyroid nodules, thyroid cancer, and thyroid disorders during pregnancy Research Focus: Thyroid nodule evaluation, molecular testing, immune checkpoint inhibitor-related thyroid dysfunction Dr. Angell's research explores the intersection of thyroid pathology, molecular diagnostics, and immune therapy complications. His 15 most recent publications (2025–2022) address topics including: Thyroid Cancer: Survival analysis in anaplastic thyroid cancer, surgical extent for medullary thyroid cancer Immune Therapy Toxicity: Mechanisms of checkpoint inhibitor diabetes and thyroiditis, JAK inhibitor interventions Diagnostic Innovation: Afirma genomic classifiers for medullary and indeterminate nodules Population Health: Environmental and social determinants of thyroid function in pregnancy Dr. Angell has received funding from the American Thyroid Association Research Grant and contributes to editorial boards of Thyroid and the Journal of Clinical Endocrinology and Metabolism . He actively participates in the American Thyroid Association Thyroid Nodule Guidelines Taskforce and the International Thyroid Oncology Group .

• Breast Cancer Genetics
• Oncology
• BRCA Mutations
• +2 more

Delal Akdeniz is a cancer researcher at Erasmus MC's Department of General Practice, focusing on contralateral breast cancer risk in BRCA carriers. Her work combines epidemiological methods with clinical oncology to inform prevention strategies. Key studies examine radiation and chemotherapy impacts on secondary cancer development using nationwide cohorts. She contributes to international collaborations like HEBON (Hereditary Breast and Ovarian Cancer Research Netherlands), developing risk prediction models for high-risk populations.